Deals channel feed

Af­ter Ver­sa­nis suc­cess, Adi­tum launch­es Celex­or Bio with au­toim­mune drug from Ace­lyrin part­ner In­ma­gene

Last year
Financing
Startups

Genen­tech gets gluey, pay­ing $47M up­front to Ori­o­n­is for de­grad­er dis­cov­ery deal

Last year

Benev­o­len­tAI, Ex­sci­en­tia on the come­back trail af­ter se­cur­ing sep­a­rate AI drug dis­cov­ery deals with Mer­ck KGaA

Last year
AI

Up­dat­ed: Roche’s Genen­tech wades in­to ra­dio­phar­ma­ceu­ti­cals with Pep­tiDream al­liance, $40M up­front

Last year

No­var­tis hands back PD-1 in­hibitor to BeiGene af­ter reg­u­la­to­ry hur­dles

Last year
R&D
FDA+

Ab­cam finds founder’s op­po­si­tion to Dana­her deal ‘sur­pris­ing,’ say­ing he's sow­ing 'con­fu­sion for share­hold­er­s'

Last year
People

Ab­b­Vie turns its back on Har­poon’s BC­MA-tar­get­ing mul­ti­ple myelo­ma drug

Last year
R&D

Roy­al­ty Phar­ma ex­ecs shed light on strat­e­gy be­hind their first gene ther­a­py deal

Last year
Cell/Gene Tx

Ex­elix­is li­cens­es small mol­e­cule from In­sil­i­co for $80M up­front; Ver­tex buys GPCR from Septer­na

Last year

Mod­er­na strikes $1.8B can­cer re­search deal with Im­mat­ics 

Last year

Verge Ge­nomics teams up with As­traZeneca in drug dis­cov­ery deal

Last year

Ot­su­ka pens AAV deal with Shape Ther­a­peu­tics for eye gene ther­a­pies

Last year
Cell/Gene Tx

Seagen teams up with pro­tein degra­da­tion spe­cial­ist to make a new kind of an­ti­body con­ju­gate, pay­ing $60M up­front

Last year

Kriya Ther­a­peu­tics buys sci­en­tif­ic ad­vi­sor’s NASH gene ther­a­py com­pa­ny

Last year
Pharma

Amid aproci­ten­tan’s reg­u­la­to­ry re­view, Idor­sia is buy­ing back the hy­per­ten­sion drug from J&J in $350M deal

Last year
FDA+

Nestlé parts with peanut al­ler­gy treat­ment Pal­forzia

Last year
Pharma

Bio­gen se­cures $1.5B loan to fund Rea­ta buy­out, with three-year re­pay­ment sched­ule baked in

Last year
Financing

Pri­vate eq­ui­ty firm Per­mi­ra buys phar­ma ser­vice provider Er­gomed in £703.1M deal

Last year

Am­gen and Hori­zon can close their $28B deal af­ter re­solv­ing law­suit by the FTC

Last year
Pharma

Zevra beefs up rare dis­ease port­fo­lio via $91M ac­qui­si­tion of Ac­er Ther­a­peu­tics

Last year
R&D

Ot­su­ka to ac­quire psy­che­del­ic drug dis­cov­ery out­fit Mind­set Phar­ma

Last year

Lil­ly qui­et­ly com­pletes pur­chase of Pad­cev com­peti­tor, es­ti­mat­ed at near­ly half a bil­lion dol­lars

Last year
Startups
Pharma

Up­dat­ed: No­vo Nordisk bags new obe­si­ty tar­get in lat­est biotech ac­qui­si­tion, inks R&D deal with spin­out

Last year

WHO se­cures three li­cens­ing deals to boost Covid vac­cine and as­say prod­uct op­tions

Last year
Coronavirus
Manufacturing
First page Previous page 27282930313233 Next page Last page
A service from the Financial Times